Eli Lilly lifts annual revenue forecast as obesity and diabetes drug demand stays strong

• The global obesity drug market reached $66 billion in 2025 and is expected to grow significantly by 2030 in the U.S. alone
• Lilly's strong results demonstrate resilient demand for its GLP-1 treatments despite pricing pressure and competition
• Rival Novo Nordisk also raised its full-year forecast, relying on its oral Wegovy pill to compete in the lucrative obesity market

Summary: Eli Lilly Raises Annual Revenue Forecast on Strong GLP-1 Drug Demand

Key Developments:

Eli Lilly lifted its full-year revenue forecast on Wednesday, August 5, driven by robust demand for its GLP-1 weight-loss and diabetes medications. The company now projects 2026 revenue of $85-87 billion, up from its prior forecast of $82-85 billion. Adjusted earnings reached $8.38 per share.

Market Context:

The announcement follows rival Novo Nordisk's forecast increase just one day earlier, as both pharmaceutical giants compete in the rapidly expanding obesity treatment market. The global obesity drug market hit $66 billion in 2025, according to IQVIA, with U.S. market projections expected to reach significant levels by 2030.

Competitive Landscape:

Despite intensifying competition from Novo Nordisk, which launched an oral version of its weight-loss drug Wegovy in the U.S. earlier this year, and ongoing pricing pressures, Lilly's results demonstrate sustained demand resilience for its GLP-1 treatments. The strong performance is expected to reassure investors concerned about market saturation and competitive threats.

Companies Mentioned:

• Eli Lilly and Co (primary focus)
• Novo Nordisk (key competitor)

Market Implications:

The raised guidance signals continued momentum in the lucrative obesity and diabetes drug segment, validating the long-term growth potential of GLP-1 therapies. Both major players demonstrating strong performance suggests the market remains robust enough to support multiple competitors, though pricing pressure may emerge as a consideration for future margins.